StreetInsider.com News Articles

Form 8-K CytomX Therapeutics, For: May 29

Wed, 03 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260603/26599012.html

Form 8-K CytomX Therapeutics, For: May 29

Wed, 03 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260603/26599012.html

CytomX expands Regeneron collaboration, receives $37 million payment

Wed, 03 Jun 2026 08:03:02 -0400

CytomX Therapeutics Inc. (NASDAQ: CTMX) announced an expansion of its research collaboration with Regeneron Pharmaceuticals Inc. to develop conditionally-activated bispecific cancer therapies. The collaboration combines CytomX's Probody therapeutic platform with Regeneron's Veloci-Bi bispecific antibody development platform.

CytomX will receive a $37 million target selection payment for two additional programs selected under the expanded agreement. Regeneron has secured an option to select up to six additional future targets, bringing total potential target nomination, research, development, regulatory and sales-based milestones to approximately $4 billion.

The original collaboration began in 2022 and focuses on applying CytomX's biologic masking strategies with Regeneron's bispecific antibodies. The technology

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Wed, 03 Jun 2026 08:00:00 -0400

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -

- CytomX to receive $37 million target selection payment for two additional programs selected -

- Regeneron secures option to select up to 6 additional future targets bringing total potential target nomination, research, development, regulatory and sales-based milestones covered under the collaboration to up to approximately ~$4 billion -

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX)

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Wed, 03 Jun 2026 08:00:00 -0400

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -

- CytomX to receive $37 million target selection payment for two additional programs selected -

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX)

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Wed, 03 Jun 2026 08:00:00 -0400

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -

- CytomX to receive $37 million target selection payment for two additional programs selected -

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX)

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Wed, 03 Jun 2026 08:00:00 -0400

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms -

- CytomX to receive $37 million target selection payment for two additional programs selected -

SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX)

CytomX Therapeutics to Present at Upcoming June Investor Conferences

Thu, 21 May 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June.

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Fireside Chat: 3:10 p.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Chat: 9:20 a.m. ET
Location: Miami, FL

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com.

CytomX Therapeutics to Present at Upcoming June Investor Conferences

Thu, 21 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Fireside Chat: 3:10 p.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Chat: 9:20 a.m. ET
Location: Miami, FL

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com.

CytomX Therapeutics to Present at Upcoming June Investor Conferences

Thu, 21 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Fireside Chat: 3:10 p.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Chat: 9:20 a.m. ET
Location: Miami, FL

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com.

CytomX Therapeutics to Present at Upcoming June Investor Conferences

Thu, 21 May 2026 08:00:00 -0400

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Fireside Chat: 3:10 p.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Chat: 9:20 a.m. ET
Location: Miami, FL

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com.

Wolfe Research Starts CytomX Therapeutics (CTMX) at Outperform

Tue, 19 May 2026 05:33:30 -0400

(Updated - May 19, 2026 5:33 AM EDT)

Wolfe Research analyst Kalpit Patel initiates coverage on CytomX Therapeutics (NASDAQ: CTMX) with a Outperform rating and a price target of $3.50.

The analyst comments "The response rates in colorectal cancer are unusual. Varseta-M's confirmed response rates are ~20-32% in 3L+ mCRC -- five times what Lonsurf-bev delivers -- and these are late-line patients. The early-stage study enrolled pts with a median of 3 priors and 83% used prior anti-VEGF. Given the high response rates, we think there is opportunity to move into earlier lines. The bear case is tox, but we are not

Wolfe Research Starts CytomX Therapeutics (CTMX) at Outperform

Tue, 19 May 2026 05:33:30 -0400

(Updated - May 19, 2026 5:33 AM EDT)

Wolfe Research analyst Kalpit Patel initiates coverage on CytomX Therapeutics (NASDAQ: CTMX) with a Outperform rating and a price target of $3.50.

CytomX hires Mamata Gokhale as regulatory affairs head

Mon, 18 May 2026 08:01:22 -0400

CytomX Therapeutics Inc. (NASDAQ: CTMX) appointed Mamata Gokhale as Senior Vice President of Regulatory Affairs, according to a company statement. Gokhale will oversee the company's global regulatory strategy and engagement to support advancement of its PROBODY pipeline through clinical development.

Gokhale brings over 25 years of regulatory experience spanning early-stage clinical development through commercialization. She most recently served as VP of Global Regulatory Affairs at Perspective Therapeutics, where she led regulatory strategy for multiple oncology programs and secured expedited designations.

Prior to Perspective, Gokhale was VP of Global Regulatory Affairs at Sierra Oncology, which was acquired by GSK, where she led regulatory

CytomX hires Mamata Gokhale as regulatory affairs head

Mon, 18 May 2026 08:01:22 -0400

Prior to Perspective, Gokhale was VP of Global Regulatory Affairs at Sierra Oncology, which was acquired by GSK, where she led regulatory

CytomX hires Mamata Gokhale as regulatory affairs head

Mon, 18 May 2026 08:01:22 -0400

Prior to Perspective, Gokhale was VP of Global Regulatory Affairs at Sierra Oncology, which was acquired by GSK, where she led regulatory

CytomX hires Mamata Gokhale as regulatory affairs head

Mon, 18 May 2026 08:01:22 -0400

Prior to Perspective, Gokhale was VP of Global Regulatory Affairs at Sierra Oncology, which was acquired by GSK, where she led regulatory

CytomX hires Mamata Gokhale as regulatory affairs head

Mon, 18 May 2026 08:01:22 -0400

Prior to Perspective, Gokhale was VP of Global Regulatory Affairs at Sierra Oncology, which was acquired by GSK, where she led regulatory

CytomX hires Mamata Gokhale as regulatory affairs head

Mon, 18 May 2026 08:01:22 -0400

Prior to Perspective, Gokhale was VP of Global Regulatory Affairs at Sierra Oncology, which was acquired by GSK, where she led regulatory

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

Mon, 18 May 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. In this role, Dr. Gokhale will lead CytomX’s global regulatory strategy and oversee regulatory engagement to support the continued advancement of the Company’s PROBODY® pipeline through clinical development and toward potential commercialization.